Oct 14, 2022
Lecture at UW on Oct 13, 2022 with Valerie Daggett, AltPep CEO. Learn about her groundbreaking work in Alzheimer’s and other amyloid...
Sep 30, 2022
“Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data suggest that the treatment, called lecanemab, eases cognitive decline. The...
Aug 22, 2022
“The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke with GeekWire about AltPep’s progress on its experimental...
Apr 28, 2022
Review Full Article and Download as a PDF. By Dylan Shea and Valerie Daggett. Biophysica 2022, 2(2), 91-110; https://doi.org/10.3390/biophysica2020010 Received: 7 April 2022 / Revised: 27 April 2022 / Accepted: 27 April 2022 / Published: 28 April 2022...
Mar 1, 2022
Breakthrough designation reinforces the significant potential of SOBA-AD assay to address the unmet need in Alzheimer’s Disease (AD) detection SOBA-AD assay is designed to selectively detect toxic oligomers that trigger a cascade of events associated with AD,...
Feb 28, 2022
SEATTLE, WA – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product...
Recent Comments